Routine immunisation schedules for Wales
Click on the links in the table for more information about the disease each vaccine protects against.
The complete routine immunisation schedule for Wales from January 2026
| Age due | Diseases protected against | Vaccine | Name | Usual site |
|---|---|---|---|---|
| 8 weeks old |
Diphtheria, tetanus, pertussis (whooping cough), polio, haemophilus influenzae type b (Hib) and hepatitis B |
DTaP/IPV/Hib/ HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Thigh |
| 8 weeks old | Meningococcal group B (MenB) | MenB | Bexsero® | Thigh |
| 8 weeks old | Rotavirus gastroenteritis | Rotavirus | Rotarix® | By mouth |
| 12 weeks old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB | Infanrix hexa® or Vaxelis® | Thigh |
| 12 weeks old | Meningococcal group B (MenB) | MenB | Bexero® | Thigh |
| 12 weeks old | Rotavirus gastroenteritis | Rotavirus | Rotarix® | By mouth |
| 16 weeks old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | DTaP/IPV/Hib/ HepB | Infanrix hexa®or Vaxelis® | Thigh |
| 16 weeks old | Pneumococcal | PCV 13 | Prevenar 13®1 | Thigh |
| 12 months old | Pneumococcal | PCV 13 | Prevenar 13®1 | Upper arm/ thigh |
| 12 months old | Meningococcal group B (MenB) | Men B | Bexero® | Upper arm/ thigh |
| 12 months old | Measles, mumps and rubella | MMR | ProQuad® or Priorix-Tetra® | Upper arm/ thigh |
| 18 months old |
Born before 1 July 2024: No appointment Born on or after 1 July 2024: Measles, mumps and rubella |
MMR | ProQuad® or Priorix-Tetra® | Upper arm/thigh |
| 18 months old |
Born before 1 July 2024: No appointment Born on or after 1 July 2024: Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B |
DTaP/IPV/Hib/HepB (6-in-1) | Infanrix hexa® or Vaxelis® | Upper arm/thigh |
| 22 and 3 years old and all school aged children | Influenza (annually from September) | Live attenuated influenza vaccine | Fluenz®3 | Both nostrils |
| 3 years 4 months old | Diphtheria, tetanus, pertussis, polio, Hib and hepatitis B | dTaP/IPV (4-in-1) | Boostrix-IPV® or Repevax® | Upper arm |
| 3 years 4 months old |
Born before 1 January 2025: Measles, mumps and rubella Born on or after 1 January 2025: No MMRV vaccine |
MMRV | ProQuad® or Priorix-Tetra® | Upper arm |
|
School year 8 (12 to 13 year olds) |
Cancers and genital warts caused by specific human papillomavirus (HPV) types | HPV4 (one dose) | Gardasil 9® | Upper arm |
|
School year 9 (13 and 14 year olds) |
Tetanus, diphtheria and polio | Td/IPV (3-in-1) (check MMR status) | Revaxis® | Upper arm |
|
School year 9 (13 and 14 year olds) |
Meningococcal groups A, C, W and Y | MenACWY | Nimenrix® or MenQuadfi® | Upper arm |
| 65 years of age and older | Influenza (annually) | Inactivated influenza vaccine |
Adjuvanted trivalent influenza vaccine (aTIV) or Cell-based trivalent influenza vaccine (TIVc)5 |
Upper arm |
| 65 years of age | Pneumococcal | PPV23 or PCV206 | Pneumovax 23® or Prevenar 20® | Upper arm |
|
65 years old and 70 to 79 years old (plus people from age 18 with severe immunosuppression)7 |
Shingles | Shingles | Shingrix® | Upper arm |
| 75 years | Respiratory Syncytial Virus (RSV) | RSV | Abrysvo® | Upper arm |
1 Refer to the Green Book Chapter: Pneumococcal – table 25.3 (external site) for babies with asplenia, splenic dysfunction, complement disorder or severely immunocompromised.
2 Children must be 2 years old by 31 August to receive influenza vaccine in the routine programme in autumn/winter
3 If Fluenz® is unsuitable, use inactivated flu vaccine.
4 Check the relevant chapter of the Green Book for individuals requiring a 3-dose schedule.
5 Only use TIVc if no aTIV stock is available or if aTIV is unsuitable.
6 PCV20 is expected to replace PPV23 in early 2026.
Selective immunisation programmes
| Target group | Age and schedule | Disease | Vaccines |
|---|---|---|---|
| Babies born to hepatitis B infected mothers | At birth and 1 month old1 | Hepatitis B |
Hepatitis B vaccines (Engerix B® / HBvaxPRO®) |
| Infants in areas of the country with TB incidence >= 40/100,000 | From birth | Tuberculosis | BCG® |
| Infants with a parent or grandparent born in a high incidence country2 |
From birth |
Tuberculosis |
BCG® |
| People in a risk group for influenza3 | From 6 months to 64 years | Influenza | Age-appropriate flu vaccine3 |
| Pregnant women | From 16 weeks of pregnancy | Pertussis |
Tdap (ADACEL®) If ADACEL® is unavailable or contraindicated, administer dTaP/IPV (Boostrix-IPV® or Repevax®) |
| Pregnant women | From 28 weeks of pregnancy | Respiratory syncytial virus (RSV) | Abrysvo® |
| Pregnant women | At any stage in pregnancy during the flu season | Influenza | Recommended inactivated flu vaccine3 |
| Gay, bisexual and other men who have sex with men |
45 years of age and under4 |
HPV4 | Gardasil 9® |
| People at increased risk of mpox | Based on risk | Mpox | Imvanex® |
| People at increased risk of gonorrhoea | Based on risk | Gonorrhoea | Bexsero® |
1 In addition to hexavalent vaccine (Infanrix hexa or Vaxelis) given at 8, 12, 16 weeks and 18 months. Take blood for HBsAg to exclude infection at 12 to 18 months.
2 Where the annual incidence of TB is >= 40/100,000 see the WHO country profile (external site).
3 Refer to annual flu Welsh Health Circular (external site) for eligibility criteria and vaccine recommendations
4 Check the Green Book Chapter: HPV (external site) for individuals requiring a 1, 2 or 3 dose schedule.
5A sexual health clinician will assess individuals attending the sexual health clinic and advise vaccination if required
Additional vaccines for individuals with underlying medical conditions1
| Medical condition | Diseases protected against | Vaccines required2 |
|---|---|---|
| Asplenia, splenic dysfunction or complement disorder (Including people with coeliac disease who have splenic dysfunction, and all haemoglobinopathies such as homozygous sickle cell disease) |
Meningococcal groups A, B, C, W and Y Pneumococcal Influenza |
MenACWY MenB PCV13® or PCV20 (up to two years of age)3 PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
| Cochlear implants, cerebrospinal fluid leaks | Pneumococcal | PPV23 or PCV20 (from two years of age)4 |
|
Chronic respiratory and heart conditions (such as moderate to severe asthma, chronic pulmonary disease, and heart failure) |
Pneumococcal Influenza |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
|
Chronic neurological conditions (such as Parkinson’s or motor neurone disease, or learning disability) |
Pneumococcal (only if the individual is also at increased risk of aspiration) Influenza |
PPV23 (from two years of age)4 Annual flu vaccine5 |
| Diabetes |
Pneumococcal Influenza |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 |
|
Chronic kidney disease (CKD) (including haemodialysis) |
Pneumococcal (stage 4 and 5 CKD) Influenza (stage 3, 4 and 5 CKD) Hepatitis B (stage 4 and 5 CKD) |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Hepatitis B |
| Chronic liver conditions |
Pneumococcal Influenza Hepatitis A & B |
PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Hepatitis A & Hepatitis B |
| Haemophilia | Hepatitis A & B | Hepatitis A & B |
| Immunosuppression due to disease or treatment |
Pneumococcal Influenza Shingles |
PCV13 or PCV20 (up to two years of age)3 PPV23 or PCV20 (from two years of age)4 Annual flu vaccine5 Shingrix (aged 18 years and over) |
1 The list is not exhaustive. Other vaccines may be recommended for certain individuals.
2 Check relevant chapter of the Green Book (external site) for specific schedule and for further detail.
3 See table 25.3 – Summary of vaccine doses for at-risk patients in the Green Book, Chapter 25 about pneumococcal on the UK Government website (external site) for further information.
4 Refer to the Green Book Chapter: Pneumococcal (external site) for detailed guidance on vaccine recommendations for this clinical risk group. PCV20 is expected to replace PPV23 in late 2025 or early 2026.
5 From six months of age.
6 Consider annual influenza vaccination for household members and those who care for people with these conditions.